Other Information.
+Added: On June 1, 2023, Sean McCarthy, Chief Executive Officer and Chairman, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 109,768 shares of the Company’s common stock between January 1, 2024 and February 7, 2025.
+Added: CytomX Therapeutics, Inc.
Incorporated by Reference
5 unchanged sentences
Specimen Common Stock Certificate
−Removed: Sublease Agreement dated as of March 24, 2023, by and between CytomX Therapeutics, Inc and Atomic AI, Inc.
+Added: Form of Pre-Funded Warrant
+Added: Form of Tranche Warrant
+Added: Amendment No.
+Added: 3 to the Collaboration and License Agreement, dated as of May 18, 2023, by and between CytomX Therapeutics, Inc.
+Added: and Amgen, Inc.
+Added: Form of Amended and Restated Severance and Change of Control Agreement by and between CytomX Therapeutics, Inc.
+Added: and each of its executive officers other than Sean A.
+Added: Employment Offer Letter Agreement between CytomX Therapeutics, Inc.
+Added: and Jeffrey Landau dated as of March 31, 2021.
+Added: Unit Purchase Agreement by and among the CytomX Therapeutics, Inc.
+Added: and certain accredited investors named therein, dated June 29, 2023.
Certification of Chief Executive Principal required by Rule 13a-14(a) or Rule 15d-14(a).
8 unchanged sentences
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
+Added: CytomX Therapeutics, Inc.
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
+Added: Certain confidential portions of this exhibit have been omitted from this exhibit.
+Added: # Indicates management contract or compensatory plan.
* The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of CytomX Therapeutics, Inc.
under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.
+Added: CytomX Therapeutics, Inc.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CytomX Therapeutics, Inc.
+Added: August 8, 2023
Chief Executive Officer and Chairman
(Principal Executive Officer)
+Added: August 8, 2023
/s/ Christopher W.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.